StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) stock

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)

Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –

Earnings

BeOne Medicines's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 5, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$1.71B
+29.6% on a year earlier
Adjusted diluted EPS per ADS, Q2 FY2026
$3.84
$2.25 a year earlier
Latest guidance
Issued
Aug 5, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of BeOne Medicines's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Nov 5, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Aug 5, 2026before the open$1.71B+29.6%$0.16$3.84Release
Q1 FY2026ended Mar 31, 2026May 6, 2026before the open$1.50B+36.4%$1.96$3.24Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$1.50B–$0.58$1.95Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open$1.40B+39.7%$1.09$2.65Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025before the open$1.32B+41.6%$0.84$2.25Release
Q1 FY2025ended Mar 31, 2025May 7, 2025before the open$1.10B+46.3%$0.01$1.22Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open––-$0.11–Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open$1.00B+28.2%––Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024before the open$929.00M+56.1%-$0.09–Release
Q1 FY2024ended Mar 31, 2024May 8, 2024before the open$752.00M+67.9%-$0.19–Release
Q4 FY2023ended Dec 31, 2023Feb 26, 2024before the open$634.40M+66.9%-$0.27–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

BeOne Medicines's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenueFY2026$6.30B – $6.50B–NewMay 6, 2026
Total revenueFY2026$6.20B – $6.40B–NewFeb 26, 2026
GAAP operating incomeGAAPFY2026$750.00M – $850.00M–NewMay 6, 2026
GAAP operating incomeGAAPFY2026$700.00M – $800.00M–NewFeb 26, 2026
Non-GAAP operating incomenon-GAAPFY2026$1.45B – $1.55B–NewMay 6, 2026
Non-GAAP operating incomenon-GAAPFY2026$1.40B – $1.50B–NewFeb 26, 2026
Diluted ADS outstandingFY2026118–NewAug 5, 2026
Diluted ADS outstandingFY2026118–NewMay 6, 2026
GAAP operating expensesGAAPFY2026$4.70B – $4.90B–NewMay 6, 2026
GAAP operating expenses (combined R&D and SG&A)GAAPFY2026$4.70B – $4.90B–NewFeb 26, 2026
Other income (expense)FY2026$25.00M – $50.00M–NewAug 5, 2026
Other income (expense)FY2026$25.00M – $50.00M–NewMay 6, 2026

Guidance vs results

The last range BeOne Medicines gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$5.10B – $5.30B$5.31BΣ4QAbove range

Guidance history

Every forecast BeOne Medicines put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 5, 2026Diluted ADS outstandingFY2026118New
Aug 5, 2026Other income (expense)FY2026$25.00M – $50.00MNew
May 6, 2026GAAP operating incomeFY2026$750.00M – $850.00MNew
May 6, 2026Non-GAAP operating incomeFY2026$1.45B – $1.55BNew
May 6, 2026Diluted ADS outstandingFY2026118New
May 6, 2026Other income (expense)FY2026$25.00M – $50.00MNew
May 6, 2026GAAP operating expensesFY2026$4.70B – $4.90BNew
May 6, 2026Total revenueFY2026$6.30B – $6.50BNew
Feb 26, 2026GAAP operating incomeFY2026$700.00M – $800.00MNew
Feb 26, 2026Non-GAAP operating incomeFY2026$1.40B – $1.50BNew
Feb 26, 2026GAAP operating expenses (combined R&D and SG&A)FY2026$4.70B – $4.90BNew
Feb 26, 2026Total revenueFY2026$6.20B – $6.40BNew
Nov 6, 2025total revenueFY2025$5.10B – $5.30BNew
Aug 6, 2025GAAP Operating Expenses (R&D and SG&A)FY2025$4.10B – $4.40BNew
May 7, 2025GAAP Operating Expenses (R&D and SG&A)FY2025$4.10B – $4.40BNew
May 7, 2025total revenueFY2025$4.90B – $5.30BReaffirmed
Feb 27, 2025Total RevenueFY2025$4.90B – $5.30BNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases BeOne Medicines filed with the SEC as exhibits to Form 8-K or 6-K

  1. Key Differences between U.S. GAAP and PRC GAAP
    Results
  2. BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
    Results
  3. BeOne Medicines’ BEQALZI ™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
    News
  4. BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
    Results
  5. Key Differences between U.S. GAAP and PRC GAAP
    Results
  6. BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
    Results
  7. BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
    Results
  8. Key Differences between PRC GAAP and U.S. GAAP
    Results
  9. BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
    Update
  10. BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
    Results
  11. BeiGene Announces First Quarter 2025 Financial Results and Business Updates
    Results
  12. Key Differences between PRC GAAP and U.S. GAAP
    Results
  13. BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
    Results
  14. BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
    Results
  15. The risk factors denoted with a “*”, if any, are newly added or have been materially updated from our Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Report”).
    News